Oppenheimer raised its price target on Artivion Inc. (NYSE:AORT) to $40.00 from $32.00 on Friday, while maintaining an Outperform rating following the company’s second-quarter earnings report. The medical device company, with a market capitalization of $1.54 billion, is trading near its 52-week high of $33.39
Artivion reported second-quarter revenue of $113 million, representing 14% year-over-year growth on a pro forma, constant currency basis. The results exceeded both Oppenheimer’s and consensus estimates of $109 million and $108 million, respectively. The company maintains strong operational efficiency with a gross margin of 63.94% and a healthy liquidity position, reflected in its robust current ratio of 5.53.
The company saw significant growth across product lines, with aortic stents/grafts increasing 22% and On-X products rising 24%, driven by cross-selling initiatives and new data. A cyber incident from the fourth quarter of 2024 had a $1.7 million impact on the second quarter, with the remaining tissue backlog expected to clear by the end of the third quarter.
Artivion received FDA IDE approval to begin its Arcevo-LSA pivotal trial, with enrollment expected to start before year-end. The company also announced it had raised its full-year 2025 revenue guidance to $435-443 million from the previous $423-435 million range.
Oppenheimer cited Artivion’s consistent performance in meeting or exceeding expectations as a key factor in its decision to raise the price target, noting that AMDS and NEXUS products could further accelerate growth if current timelines hold.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.